Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06535789 · ClinicalTrials.gov registry record · Phase 2
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
A Phase 2 study of Pregnancy Complications and Glucose Metabolism Disorders, sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT06535789 is a Phase 2 study of Pregnancy Complications and Glucose Metabolism Disorders that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 30 participants, below the 3,790-participant average among 39 other Pregnancy Complications trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06535789, a Phase 2 study of Pregnancy Complications and Glucose Metabolism Disorders, is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.
Conditions Studied
Interventions
- DRUG Inhaled Technosphere Insulin
Study Locations (5)
California
- Sansum Diabetes Research Institute - Santa Barbara
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
New York
- Icahn School of Medicine at Mount Sinai - New York
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06535789
The ClinicalTrials.gov registry entry for NCT06535789 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,790-participant average among 39 other Pregnancy Complications trials with a reported enrollment target (99% lower). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pregnancy Complications appearing as the primary indexed condition, and to 1 intervention - of which Inhaled Technosphere Insulin is the first listed.
NCT06535789 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT06535789 about?
NCT06535789 is a clinical study titled "Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes". Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and aft...
What is the current status of trial NCT06535789?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-05. Estimated completion is 2025-07.
What conditions does trial NCT06535789 study?
This clinical trial studies the following conditions: Pregnancy Complications, Glucose Metabolism Disorders, Diabetes, Gestational, Glucose Intolerance During Pregnancy.
What interventions are being tested in trial NCT06535789?
The interventions under investigation include: Inhaled Technosphere Insulin (DRUG).
Who is sponsoring clinical trial NCT06535789?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06535789 being conducted?
This trial has 5 study locations across California, Colorado, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Delivering HOPE (Helping Women Optimize Prenatal Equity)
RECRUITING · NA
-
Better Lifestyle Counseling for African American Women During Pregnancy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.